GlassScriptPhysician profile
Noel D Saks
NPI 1528018215
$3,641.66
in general payments reported to CMS, 2019-2025
23 companies · $918 in 2025
The $918 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $263 · 2021: $181 · 2022: $498 · 2023: $978 · 2024: $578 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $886.23 | 2019-2023 | Tepezza |
| Abbvie INC. | $563.46 | 2022-2025 | Botox |
| Amgen INC. | $543.46 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $243.08 | 2023-2024 | Acthar |
| Oyster Point Pharma, INC. | $190.92 | 2022-2024 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $186.46 | 2022-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Sun Pharmaceutical Industries INC. | $172.87 | 2023-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $138.16 | 2024-2025 | Xdemvy |
| Genentech USA, INC. | $131.75 | 2022 | |
| Biotissue Holdings INC. | $93.75 | 2023 | |
| Bausch & Lomb Americas INC. | $90.25 | 2022-2023 | Vyzulta, Miebo |
| Aerie Pharmaceuticals, INC. | $71.07 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $68.64 | 2025 | Xeomin |
| Thea Pharma INC. | $43.32 | 2023 | Iyuzeh |
| Allergan, INC. | $40.06 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $36.74 | 2024-2025 | Vevye |
| Ani Pharmaceuticals, INC. | $30.50 | 2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $20.75 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.44 | 2019 | |
| Tearlab Corp | $18.70 | 2023 | Tearlab Osmolarity System |
| Abbott Laboratories | $18.63 | 2024 | Proclaim |
| Dompe US, INC. | $18.37 | 2024 | Oxervate |
| Apellis Pharmaceuticals, INC. | $14.05 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Saks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.